To the Editor Leong and colleagues1 performed an important retrospective cohort study to assess the risk of MACE between patients with and without chronic myeloid leukaemia (CML), with subgroup analysis by patients present before and after the market introduction of tyrosine kinase inhibitors (TKIs) (cut-off at 2001). However, the cohort design has several limitations. While the cut-point by TKI marketing at first seems logical, TKIs as a group have drastically changed since the early 2000s. For example, TKI access was often restricted among older adults because initial studies showed the greatest survival benefit in younger patients.2 Also, many patients who were diagnosed prior to 2001 were eventually treated with TKIs. Furthermore, later-generation TKIs …

中文翻译：

---

酪氨酸激酶抑制剂治疗慢性粒细胞白血病患者的不良结果

致编辑 Leong 及其同事 1 进行了一项重要的回顾性队列研究，以评估患有和不患有慢性粒细胞白血病 (CML) 的患者发生 MACE 的风险，并对酪氨酸激酶抑制剂 (TKI) 上市前后存在的患者进行亚组分析。 2001 年截止）。然而，队列设计有几个限制。虽然 TKI 营销的切入点起初似乎合乎逻辑，但自 2000 年代初以来，TKI 作为一个整体发生了巨大变化。例如，老年人使用 TKI 往往受到限制，因为最初的研究表明，年轻患者的生存获益最大。2此外，许多在 2001 年之前确诊的患者最终接受了 TKI 治疗。此外，下一代 TKI ……